Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years.
colorectal cancer
epidemiology
screening
Journal
Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
13
09
2018
revised:
29
03
2019
accepted:
31
03
2019
pubmed:
18
5
2019
medline:
18
10
2019
entrez:
18
5
2019
Statut:
ppublish
Résumé
The incidence of colorectal cancer (CRC) declines among subjects aged 50 years and above. An opposite trend appears among younger adults. In Europe, data on CRC incidence among younger adults are lacking. We therefore aimed to analyse European trends in CRC incidence and mortality in subjects younger than 50 years. Data on age-related CRC incidence and mortality between 1990 and 2016 were retrieved from national and regional cancer registries. Trends were analysed by Joinpoint regression and expressed as annual percent change. We retrieved data on 143.7 million people aged 20-49 years from 20 European countries. Of them, 187 918 (0.13%) were diagnosed with CRC. On average, CRC incidence increased with 7.9% per year among subjects aged 20-29 years from 2004 to 2016. The increase in the age group of 30-39 years was 4.9% per year from 2005 to 2016, the increase in the age group of 40-49 years was 1.6% per year from 2004 to 2016. This increase started earliest in subjects aged 20-29 years, and 10-20 years later in those aged 30-39 and 40-49 years. This is consistent with an age-cohort phenomenon. Although in most European countries the CRC incidence had risen, some heterogeneity was found between countries. CRC mortality did not significantly change among the youngest adults, but decreased with 1.1%per year between 1990 and 2016 and 2.4% per year between 1990 and 2009 among those aged 30-39 years and 40-49 years, respectively. CRC incidence rises among young adults in Europe. The cause for this trend needs to be elucidated. Clinicians should be aware of this trend. If the trend continues, screening guidelines may need to be reconsidered.
Identifiants
pubmed: 31097539
pii: gutjnl-2018-317592
doi: 10.1136/gutjnl-2018-317592
pmc: PMC6839794
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1820-1826Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
JAMA. 2008 Dec 17;300(23):2765-78
pubmed: 19088354
JAMA Oncol. 2015 Jul;1(4):505-27
pubmed: 26181261
Int J Cancer. 2004 Jan 20;108(3):433-42
pubmed: 14648711
Cancer Epidemiol. 2016 Jun;42:90-100
pubmed: 27060626
Annu Rev Immunol. 2011;29:415-45
pubmed: 21219177
CA Cancer J Clin. 2018 Jul;68(4):250-281
pubmed: 29846947
Gut. 2018 Feb;67(2):291-298
pubmed: 27733426
Cancer Causes Control. 2013 Feb;24(2):335-41
pubmed: 23224326
Front Public Health. 2017 Jul 24;5:179
pubmed: 28791283
Gut. 2017 Apr;66(4):683-691
pubmed: 26818619
Cancer Causes Control. 1995 Mar;6(2):164-79
pubmed: 7749056
Cancer. 2018 Jul 15;124(14):2964-2973
pubmed: 29846933
Br J Cancer. 2009 Feb 24;100(4):611-6
pubmed: 19209175
Am J Epidemiol. 2015 Jun 1;181(11):832-45
pubmed: 25888582
Curr Treat Options Oncol. 2017 Apr;18(4):23
pubmed: 28391421
Ann Oncol. 2011 Sep;22(9):1958-72
pubmed: 21307158
Curr Treat Options Oncol. 2017 Sep 25;18(10):64
pubmed: 28948490
Am J Gastroenterol. 2011 Nov;106(11):1911-21; quiz 1922
pubmed: 21912438
Am J Clin Nutr. 2007 Sep;86(3):556-65
pubmed: 17823417